Weekly Analysts’ Ratings Updates for Jade Biosciences (JBIO)

Several analysts have recently updated their ratings and price targets for Jade Biosciences (NASDAQ: JBIO):

• 1/7/2026 – Jade Biosciences is now covered by analysts at HC Wainwright. They set a “buy” rating and a $25.00 price target on the stock.
• 1/7/2026 – Jade Biosciences is now covered by analysts at HC Wainwright. They set a “buy” rating and a $25.00 price target on the stock.
• 12/29/2025 – Jade Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Jade Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Jade Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Jade Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Jade Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Jade Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/18/2025 – Jade Biosciences had its price target raised by analysts at Guggenheim from $14.00 to $17.00. They now have a “buy” rating on the stock.
• 11/15/2025 – Jade Biosciences was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.